Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD
11.61
+1.02 (9.63%)
Jul 6, 2022 4:00 PM EDT - Market closed

Company Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.

The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.

Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.
Country United States
Founded 2019
IPO Date Jun 24, 2021
Industry Biotechnology
Sector Health Care
Employees 95

Contact Details

Address:
645 Summer Street
Boston, MA 02210
United States
Phone 617 949 2643
Website monterosatx.com

Stock Details

Ticker Symbol GLUE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $19.00
CIK Code 1826457
ISIN Number US61225M1027
SIC Code 2836

Key Executives

Name Position
Dr. Markus Warmuth M.D. President, Chief Executive Officer and Director
Dr. Owen B. Wallace Ph.D. Chief Scientific Officer
Dr. Filip Janku M.D., Ph.D. Chief Medical Officer
Ajim A. Tamboli C.F.A. Chief Financial Officer
Jennifer Champoux Senior Vice President of Operations
Dr. Sharon Townson Ph.D. Chief Technology Officer
Phil Nickson J.D., Ph.D. General Counsel
Dr. John C. Castle Ph.D. Chief Data Scientist
Dr. Jullian G. Jones J.D., M.B.A., Ph.D. Chief Business Officer
Dr. Silvia Buonamici Ph.D. Senior Vice President of Drug Discovery Biology

Latest SEC Filings

Date Type Title
Jul 1, 2022 S-3 Registration statement under Securities Act of 1933
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 8-K Current report
Jun 8, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 11, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 11, 2022 8-K Current report